Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia.
Serio
M
M
Endocrinology Unit, University of Florence, Italy.
Fiorelli
G
G
D058891:5-alpha Reductase Inhibitors; D000728:Androgens / Q000494:pharmacology / Q000502:physiology*; D000736:Androstenes / Q000494:pharmacology / Q000627:therapeutic use; D001378:Azasteroids / Q000494:pharmacology / Q000627:therapeutic use; D002277:Carcinoma / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D013196:Dihydrotestosterone / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000502:physiology; D018120:Finasteride; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000502:physiology; D008297:Male; D010455:Peptides / Q000494:pharmacology / Q000502:physiology*; D011467:Prostate / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D011471:Prostatic Neoplasms / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D058891:5-alpha Reductase Inhibitors; D000728:Androgens; D000736:Androstenes; D001378:Azasteroids; D006133:Growth Substances; D010455:Peptides; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; D018120:Finasteride; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I